Grifols opens its key week with a rise of almost 3%, leading the rises of the Ibex 35

MADRID, 26 Feb.

Grifols opens its key week with a rise of almost 3%, leading the rises of the Ibex 35


Grifols shares opened this Monday leading the rise of the Ibex 35, advancing almost 3% around 9:08 a.m., in a key week for the blood products company, since it will predictably publish its latest accounts with the family on Thursday. in executive positions after the Gotham offensive.

In this way, Grifols shares began trading at a price of 11.825 euros per share, with an increase of 2.87%, although minutes later it reduced its momentum to 2.35%, until trading at 11.765 euros.

The company will predictably publish this Thursday, February 29, its latest annual accounts with Raimon Grifols, Víctor Grifols Deu and Albert Grifols Coma-Cros holding executive positions within its board of directors, in a context marked by the company's crisis of blood products after the latest offensive launched by Gotham City Research questioning its accounts and sustainability.

Specifically, the company, which announced changes in its governance at the beginning of the month, has appointed Nacho Abia as CEO, with effect from April 1 and has kept Thomas Glanzmann as executive president, while Raimon Grifols, Víctor Grifols Deu and Albert Grifols Coma-Cros remain as proprietary directors.

Thus, the three members of the family have ended their executive stage within the Catalan company, leaving their functions as corporate director, director of operations and executive director, respectively.

These changes in its governance, which are part of a corporate governance strategy "planned and initiated in 2022" and which was promoted by Raimon Grifols and Víctor Grifols Deu together with the board of directors of the multinational, were announced by the company with the purpose of separating the management of the property, in the hands of the family of the blood products firm.

Grifols obtained a profit of 3.32 million euros between January and September of last year, which represents a decrease of 98.2% compared to the same period in 2022.

For its part, the bearish fund Gotham City Research attacked Grifols for the second time on February 20, posing, on this occasion, a battery of seven questions related to the nature of the relationship between the company and the Scranton family office. linked to the Grifols family.

Given the changes in Grifols' governance, Gotham pointed out that its previous complaints, published on January 9, were what motivated changes in its corporate governance, resulting in the separation of family members from the management of the company. blood derivatives.

Gotham also referred to the conference call that Grifols held on January 11 in response to its first report, in which it indicated that the links with Scranton refer only to two specific collaborations: the rental of the Grifols headquarters, which exists since 2012 as a result of the acquisition of Talecris, and Haema and BPC since 2018, ensuring that there are no other links between the companies.

Faced with this second offensive, Grifols responded to the bearish fund that it has already responded "to each of its malicious and misleading questions", and "categorically" denied in a statement to the National Securities Market Commission (CNMV) "the malicious insinuations, "false and misleading statements from Gotham with the sole objective of destabilizing the company and raising doubts among institutional investors."

On the other hand, the minority shareholders asked the CNMV for the file that accumulates all the financial information of Grifols and reported that the supervisor has denied this request due to "technical issues", as sources from the Spanish Association of Minority Shareholders have informed Europa Press. of Listed Companies (Aemec).